February 2014 - BioEnterprise

Monthly Healthcare Review
February 2014
IPOs
The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.
Company
Date
Description
Size
Amedica Corp.
13-Feb-14
AMDA
Amedica Corp. is a Salt Lake City, UT- based provider of silicon nitride
technology platform. The company produces silicon nitride in four forms,
which are, for example, used in the cervical and thoracolumbar areas of the
spine
$20.00 million
Lead Manager
JMP Securities
Argos Therapeutics Inc.
7-Feb-14
ARGS
Argos Therapeutics Inc. is a Durham, NC-based developer of personalized
immunotherapies for the treatment of cancer and infectious diseases.
$45.00 million
Undisclosed.
Auspex Pharmaceuticals Inc. 7-Feb-14
ASPX
Auspex Pharmaceuticals Inc. is a La Jolla, CA-based developer of medicines
for the treatment of orphan diseases.
$84.00 million
Undisclosed.
7-Feb-14
BIOC
Biocept Inc. is a San Diego, CA-based provider of circulating tumor cell tests.
$19.00 million
Undisclosed.
Concert Pharmaceuticals Inc. 13-Feb-14
CNCE
Concert Pharmaceuticals Inc. is a Lexington, MA- based developer of small
molecule drugs. The company is focused on using deuterium chemistry to
provide better pharmacokinetic or metabolic properties in an effort to enhance
clinical safety, tolerability, and efficacy.
$84.00 million
UBS Investment Bank
Wells Fargo Securities
Eagle Pharmaceuticals Inc.
12-Feb-14
EGRX
Eagle Pharmaceuticals Inc. is a Woodcliff Lake, NJ-based developer of
injectable products for the critical care and oncology sectors.The two flagship
products are intravenous versions of a chemotherapeutic agent and a therapy
for malignant hyperthermia.
$50.3 million
Cantor Fitzgerald
Egalet Corp.
12-Feb-14
EGLT
Egalet Corp. is a Wayne, PA-based developer of abuse-deterrent oral products
for the treatment of pain.
$50.40 million
Undisclosed.
Eleven Biotherapeutics Inc.
6-Feb-14
EBIO
Eleven Biotherapeutics Inc. is a Cambridge, MA-based developer of protein
therapeutics to treat diseases of the eye based on the role of cytokines.
$50.00 million
Undisclosed.
Biocept Inc.
Ticker
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
Monthly Healthcare Review
February 2014
IPOs
The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.
Company
Date
Ticker
Description
Size
Lead Manager
Flexion Therapeutics Inc.
12-Feb-14
FLXN
Flexion Therapeutics Inc. is a Burlington, MA- based developer of long-acting,
injectable pain therapies. The company is targeting anti-inflammatory and
analgesic therapies for the treatment of patients with musculoskeletal
conditions, primarily osteoarthritis.
$65.00 million
BMO Capital Markets
Wells Fargo Securities
Genocea Biosciences Inc.
12-Feb-14
GNCA
Genocea Biosciences Inc. is a Cambridge, MA-based developer of vaccines to
address infectious diseases.
$66.00 million
Undisclosed.
Inogen Inc.
13-Feb-14
INGN
Inogen Inc. is a Goleta, CA- based provider of portable oxygen concentrators
used to deliver supplemental long-term oxygen therapy. The company’s
systems concentrate the air around the patient to offer a single source of
supplemental oxygen anytime, anywhere with a portable device weighing
approximately 4.8 or 7.0 pounds.
$70.40 million
J.P. Morgan
Lumenis Ltd.
27-Feb-14
$75.00 million
Goldman Sachs, Credit Suisse
NephroGenex Inc.
11-Feb-14
NRX
NephroGenex Inc. is a Princeton, NJ-based developer of therapeutics to treat
kidney disease using pathogenic oxidative chemistries.
$37.20 million
Aegis Capital Corp.
Revance Therapeutics Inc.
11-Feb-14
RVNC
Revance Therapeutics Inc. is a Newark, California-based developer of
botulinum toxic products for multiple aesthetic and therapeutic applications.
$96.00 million
Undisclosed.
uniQure BV
5-Feb-14
QURE
uniQure BV is an Amsterdam, Netherlands-based developer of gene therapies
for genetic and acquired diseases.
$91.80 million
Undisclosed.
NASDAQ: Lumenis Ltd. is a Yokneam, Israel-based provider of energy-based, minimally
LMNS
invasive clinical solutions for the surgical, ophthalmic, and aesthetic industries.
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
Monthly Healthcare Review
February 2014
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.
Company
Date
Round
Description
Size
Lead Investors
Disposable Cubicle Curtains 25-Feb-14
Ltd.
Growth
Disposable Cubicle Curtains Ltd. is a West Sussex, UK-based
provider of infection preventative medical products which include patented
disposable curtains and blinds which are designed to actively destroy harmful
pathogens.
$5.02 million
Beringea LLC
Kerecis Inc.
21-Feb-14
Third
Kerecis Inc. is a Westfjords, Iceland-based provider of tissue-regeneration
products that can be used in reconstructive, soft- and hard-tissue surgical
procedures.
$2.00 million
NSA Ventures
Advanced Accelerator
17-Feb-14
Later
Advanced Accelerator Applications SA is a St.-Genis-Pouilly, France-based
$56.13 million
HBM Healthcare Investments
Amal Therapeutics SA
20-Feb-14
Seed
Amal Therapeutics SA is a Geneva, Switzerland-based developer of biotech
solutions to therapeutic cancer vaccines.
Undisclosed
Boehringer Ingelheim Venture
Fund
Anergis SA
5-Feb-14
Second
Anergis SA is an Epalinges, Swirzerland-based developer of immunotherapies
against allergies.
$8.83 million
BioMed Invest, Renaissance
PME, Sunstone Capital A/S.
Audion Therapeutics B.V.
10-Feb-14
First
Audion Therapeutics B.V. is an Amsterdam, Netherlands-based provider of
biopharmaceutical solutions to hearing loss. The company engages in
discovery, development and commercialization of drugs and delivery
technologies for the treatment of diseases affecting the ear, including hearing
loss.
Undisclosed
Lilly Ventures
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
Monthly Healthcare Review
February 2014
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.
Company
Date
Round
Description
Size
Lead Investors
Augbase Tech Co. Ltd
25-Feb-14
First
Bourn Hall Ltd.
2-Feb-14
Coramaze Technologies
GmbH
Augbase Tech Co. Ltd. is a Shanghai, China-based provider of an app for
chronic disease patients that allows for intelligent health management services
and personalized medical knowledges.
Undisclosed
New Gen Partners
Growth
Bourn Hall Ltd. is a Cambridge,UK-based provider of in vitro fertilization
(IVF) services.
$5.75
Mobeus Equity Partners LLP.
14-Feb-14
First
Coramaze Technologies GmbH is an Essen, Germany-based developer of a
medical device focused on treatment of heart valve diseases.
$1.63 million
High-Tech Grunderfonds, Seed
Capital Dortmund
Eli Nutrition Inc.
17-Feb-14
Seed
Eli Nutrition Inc. is a New Haven, CT-based developer of an antacid to treat
acid reflux. The company develops medicine to provide heartburn relief using
safe and natural ingredients.
$0.10 million
YEI Innovation Fund
First Aid Beverages Inc.
10-Feb-14
Second
First Aid Beverages Inc. is a Hillsborough, CA-based provider of over-thecounter (OTC) pharmaceuticals in a liquid format, which are aimed at treating
everyday conditions such as pain and upset stomach.
Undisclosed
Sofinnova Ventures Inc.,
Redmile Group
GC Aesthetics Ltd.
21-Feb-14
Second
GC Aesthetics Limited is a Dublin, Ireland-based provider of medical devices
for the global aesthetics industry and surgical markets.
$60.00 million
OrbiMed
GenomOncology LLC
5-Feb-14
Second
GenomOncology LLC is a Westlake, OH-based developer of software and
analytical tools of sequenced genomic data.
Undisclosed
TriStar Technology Ventures.
Incanthera Ltd.
1-Feb-14
Seed
Incanthera Ltd. is a Liverpool, UK-based developer of cancer therapies
focused on solid tumors.
$1.07
SPARK Ventures, Technomark
Life Sciences.
InDex Pharmaceuticals AB
25-Feb-14
Later
InDex Pharmaceuticals AB is a Stockholm, Sweden-based developer of
antisense RNA drugs as well as diagnostic and prognostic tools for unmet
medical needs within inflammation and cancer.
$20.00 million
NeoMed Management AS
Lumos Pharma Inc.
4-Feb-14
First
Lumos Pharma Inc. is an Austin, TX-based developer of treatments for the rare
disease creatine transporter deficiency (CTD).
$14.00
New Enterprise Associates,
Sante Ventures.
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
million
million
million
Monthly Healthcare Review
February 2014
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.
Company
Date
Round
Description
Size
Lead Investors
Melinta Therapeutics Inc.
10-Feb-14
Later
Melinta Therapeutics Inc. is a New Haven, CT-based developer of antibiotics
active against resistant bacteria. The company's structure-based design
methods are based on the high-resolution crystal structure of the 50S ribosome
subunit, to which known antibiotics bind, and the 3D mechanism of action of
antibiotics.
$70.00 million
Vatera Healthcare Partners
mySugr GmbH
24-Feb-14
Seed
mySugr GmbH is a Vienna, Austria-based developer of a diabetes monitoring
app. The company's mobile app allows users to manage their diabetes through
challenges and set goals.
Undisclosed
XLHealth AG
NovImmune SA
18-Feb-14
Fifth
NovImmune Sa is a Geneva, Switzerland-based developer of therapeutic
agents for inflammation, the treatment of autoimmune diseases,
immunosuppression in organ transplantation, and immunomodulation.
$66.00 million
Rosetta Capital Limited
Ornim Medical Ltd.
18-Feb-14
Later
Ornim Medical Limited is a Kfar Saba, Israel-based provider of a non-invasive
monitor device with continuous, real-time data for both blood flow and
$10.00 million
OrbiMed Israel
Pronutria
13-Feb-14
Second
Pronutria is a Cambridge, MA-based developer of a platform to prevent and
treat diseases with novel protein nutrients. The company provides a platform
for identifying protein nutrients from within the human diet.
$12.25 million
Flagship Ventures
Psyware Gmbh
18-Feb-14
First
Psyware Gmbh is an Aachen, Germany-based provider of psycholinguistic
applications.
Undisclosed
DSA Investment, S-UBG.
Quanttus
24-Feb-14
First
Quanttus is a Cambridge, MA-based developer of wearable technologies and
devices which integrate clinical-grade vital signs monitoring and contextual
analysis to help users understand and improve their health.
$19.00 million
Khosla Ventures
Raiing Medical Co.
16-Feb-14
First
Raiing Medical Co. is a Beijing, China-based developer of mobile medical
monitoring devices.
$1.64 million
Beijing Software and
Information Services Exchange
Huizhi Investment Management
Co. Ltd.
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
Monthly Healthcare Review
February 2014
Private Equity Placements and Venture Capital Rounds
The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.
Company
Date
Round
Description
Size
Lead Investors
14-Feb-14
Fourth
REGiMMUNE Corp. is a Tokyo, Japan-based developer of immune-regulatory
therapeutics to treat life-threatening diseases and debilitating disorders.
$9.20 million
Japan Asia Investment
Corporation, Nippon Venture
Capital Corp.
Remedy Pharmaceuticals Inc. 10-Feb-14
Fourth
Remedy Pharmaceuticals Inc. is a New York, NY-based developer of
neurovascular protection platform for stroke victims. The company develops
drugs to save neural tissue and therefore improve neurological damage caused
by stroke.
Undisclosed
Undisclosed
Rhenovia Pharma Ltd. is a Alsace, France-based provider of drugs for
Alzheimer's and other central nervous system (CNS) diseases. The company's
$0.54 million
Undisclosed
SynGen Inc. is a Sacramento, CA-based provider of medical systems that
harvest stem and progenitor cells from cord blood, bone marrow, peripheral
blood, and other tissues.
$2.50 million
GE Capital
Tonic Solutions Inc. is a Palo Alto, CA-based provider of a data collection
platform for patients, hospitals, and health systems. It provides a survey
builder that allows providers to create, manage, and edit all surveys and forms.
$2.50 million
Hearst Health Ventures
Versartis Inc. is a Redwood City, CA-based developer of a long-acting
recombinant human growth hormone (rhGH) for pediatric growth hormone
deficiency (GHD).
$55.00 million
Undisclosed
REGiMMUNE Corp.
Rhenovia Pharma Ltd.
12-Feb-14
First
SynGen Inc.
26-Feb-14
Credit
Tonic Solutions Inc.
21-Feb-14
First
Versartis Inc.
18-Feb-14
E
Voalte Inc.
24-Feb-14
First
Voalte Inc. is a Sarasota, FL-based provider of healthcare communication
technologies that enables care teams to communicate inside and outside of the
hospital, and connect with existing technologies.
$36.00 million
Bedford Funding Capital
Management LLC
Voyager Therapeutics Inc.
12-Feb-14
First
Voyager Therapeutics Inc. is a Cambridge, MA-based developer of gene
therapies for fatal and debilitating diseases of the central nervous system. It is
developing gene therapies for Parkinson's disease, amyotrophic lateral
sclerosis and Friedreich's ataxia, a rare inherited disease that causes nervous
system damage and movement problems.
$45.00 million
Third Rock Ventures LLC
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
Monthly Healthcare Review
February 2014
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.
Acquirer
Target
Date
Description
Transaction Value
Forest Laboratories Inc.
Aptalis Holdings Inc.
3-Feb-14
Aptalis Holdings Inc. is a Bridgewater, NJ-based provider of therapies for
cystic fibrosis and gastrointestinal disorders.
$2.90 billion.
Agenus Inc.
4-Antibody AG
13-Feb-14
4-Antibody AG is a Basel, Switzerland-based developer of therapeutic
monoclonal antibodies. The company primarily focuses in the areas of
infectious diseases, oncology, and autoimmunity/inflammation.
$10.00 million
Novartis AG
CoStim
Pharmaceuticals Inc.
17-Feb-14
CoStim Pharmaceuticals Inc. is a Boston, MA-based developer of novel
biologics targeting immune checkpoint inhibitors for oncology indications.
Undisclosed
Optum Inc.
Audax Health Solutions 19-Feb-14
Inc.
Audax Health Solutions Inc. is a Washington, D.C.-based provider of a
personal health management platform that allows consumers to track their
health, record fitness goals, research conditions, access health information and
tools, and communicate directly with other members and medical
professionals.
Undisclosed
Henry Schein, Inc.
Arseus NV
10-Feb-14
Arseus NV is a Rotterdam, Netherlands-based R&D scientific company
delivering innovative solutions and concepts to professionals and institutions
in the healthcare sector in 30 countries worldwide
Undisclosed
GE Healthcare
API Healthcare
13-Feb-14
API Healthcare is a Hartford, WI-based provider of labor management
Undisclosed
PhotoMedex
LCA-Vision
14-Feb-14
BioFire Diagnostics Inc. is a Salt Lake City, UT-based provider of clinical
diagnostics systems. The company develops and manufactures machines for
deoxyribonucleic acid (DNA) analysis including DNA amplification, real-time
thermocycling, mutation scanning, and genotyping.
$106.4 million
14-Feb-14
Opus Instruments is a Bassingbourn, United Kingdom-based developer of a
portable and lightweight IRR based camera- Osiris- specifically designed for
high-resolution infrared reflectography.
$0.79 million
Scientific Digital Imaging plc Opus Instruments
Limited
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com
Monthly Healthcare Review
February 2014
Mergers and Acquisitions
The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.
Acquirer
Target
Description
Transaction Value
Cinven Ltd.
Medpace Inc.
24-Feb-14
Date
Medpace Inc. is a Cincinnati, OH-based provider of contract research services
$915.00 million
Mitchell International Inc.
Fairpay Solutions
21-Feb-14
Fairpay Solution is a Addison, TX-based provider of inpatient, outpatient,
Undisclosed
Montagu Private Equity
D.O.R.C. Dutch
Ophthalmic Research
Center (International)
B.V.
24-Feb-14
D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. is a
Zuidland, Netherlands-based provider of surgical tools used in the treatments
of eye ailments such as cataracts and glaucoma.
$275.48 million
Compiled By: Douglas Cannon
Sources: Venture Wire, Private Equity Week, Wall Street Journal, Venture Source, SEC Filings, Company press releases, FinSMEs.com, and biospace.com

Download Report